Phoenix Life Sciences International Is Now Accepting Bids for Hemp CBD Producers and Manufacturers
December 12 2018 - 8:06AM
InvestorsHub NewsWire
Phoenix Life Sciences International Is Now
Accepting Bids for Hemp CBD Producers and
Manufacturers
Denver, CO -- December
12, 2018 -- InvestorsHub NewsWire -- Phoenix
Life Sciences International Limited (OTC: PLSI) (“Phoenix Life”), an
international adaptive healthcare solutions company, today
announced that it is now accepting bids from U.S. licensed
producers of industrial hemp to supply various products to be used
in the formulation of its botanical
pharmaceuticals.
“As we move forward
with our mission of transforming the future of global healthcare,
our next step is partnering with a GMP licensed hemp producers in
the U.S. that shares our values and mission to push botanical
pharmaceuticals forward throughout the world,” said Phoenix Life
CEO Martin Tindall. “While we build out our production capacity, we
are proud to join other well-respected companies in the space and
begin producing our products on a larger
scale.”
Phoenix Life is
seeking a Good Manufacturing Practice (GMP) licensed industrial
hemp partner for both U.S. and foreign markets to commence in
January 2019. Products requested by Phoenix Life include soft gel
capsules, atomizer inhalers and wholesale cannabidiol (CBD) oil.
All suppliers must utilize biomass that has been produced under
organic conditions, and preference will be on USDA organic
certification. The company also encourages new and innovative
manufacturers to apply for the
partnership.
Producers bidding to
partner with Phoenix Life must have a minimum production capacity
of 24,000 bottles of 120 soft gels per bottle per month (2.8mil
soft gels per month) and 1,000 atomized inhalers per month. These
capacity requirements are expected to increase in the U.S. market
in 2020.
Phoenix Life aims to
partner with the single-payer healthcare systems of both
established and emerging economies to conduct medical studies on
cannabis for diabetes and establish programs for diabetes patients
to receive the company's botanical products. Through these
partnerships, Phoenix Life hopes to recruit the best minds in the
pharmaceutical space to join its
mission.
Interested parties
should please contact supply.chain@phoenixlife.co with full contact
details and information on which products the company would like to
submit.
To learn more about
Phoenix Life Sciences International, please visit https://www.phoenixlife.co
About
Phoenix Life Sciences International
Limited
Phoenix
Life Sciences International Limited is an adaptive healthcare
solutions company. Our business is to advance research and
integrate programs and manufacturing of products that target and
treat diabetes, pain, cancer, and address psychological,
gastrointestinal, autoimmune, neurological and sleep disorders. We
strive to create partnerships and integrate these programs for
human health into communities worldwide as part of our Global
Health Initiative.
FORWARD-LOOKING
STATEMENTS
Information contained in this press release regarding
Phoenix Life Sciences International, Limited and its subsidiaries,
(the “Companies”) may constitute forward-looking statements or
statements which may be deemed or construed to be forward-looking
statements. The words “plan”, “forecast”, “anticipates”,
“estimate”, “project”, “intend”, “expect”, “should”, “believe,” and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements involve, and are
subject to, known and unknown risks, uncertainties and other
factors which could cause the Company’s actual results, performance
(financial or operating) or achievements to differ from the future
results, performance (financial or operating) or achievements
expressed or implied by such forward-looking statements. The risks,
uncertainties and other factors are more fully discussed in the
Company’s filings with the U.S. Securities and Exchange Commission.
All forward-looking statements attributable to the Companies herein
are expressly qualified in their entirety by the above-mentioned
cautionary statement. The Companies disclaim any obligation to
update forward-looking statements contained in this press release,
except as may be required by
law.
FOOD
AND DRUG ADMINISTRATION (FDA)
DISCLOSURE
These statements have
not been evaluated by the FDA and therefore the products sold by
Phoenix Life Sciences International are not available on
U.S.
LEGAL
DISCLOSURE
Phoenix Life Sciences
International does not sell or distribute any products in the
United States that are in violation of the United States Controlled
Substances Act (US.CSA). This company does not grow, sell, and
distribute cannabis-based products in the United States and is
solely involved with the legal distribution of medical
cannabis-based products within certain international markets
outside of the United States.
Investor
Contact:
Phone: 1.888.717.5655
or international +1.720.699.7222
E-mail: investor.relations@phoenixlife.co
Media
Contact:
Kathryn Reinhardt
CMW Media
Kathryn@cmwmedia.com
619-972-3089
Phoenix Life Sciences (CE) (USOTC:PLSI)
Historical Stock Chart
From Apr 2024 to May 2024
Phoenix Life Sciences (CE) (USOTC:PLSI)
Historical Stock Chart
From May 2023 to May 2024